BioCryst Pharmaceuticals grants 57,000 shares of restricted stock units to new employees.

From GlobeNewswire: 2025-07-03 07:00:00

BioCryst Pharmaceuticals, Inc. granted 57,000 shares of restricted stock units to eight new employees on July 1, 2025. The RSUs vest in four equal annual installments, subject to continued service with the company. BioCryst focuses on developing therapies for rare diseases like hereditary angioedema and has commercialized ORLADEYO®. For more information, visit www.biocryst.com. Contact John Bluth at +1 919 859 7910 or [email protected].



Read more at GlobeNewswire: BioCryst Reports Inducement Grants Under Nasdaq Listing